Loading
Sequence every cancer at diagnosis, along with the patient's inherited genes, and pool the results with treatments and outcomes so every patient teaches the system how to treat the next.
Comprehensive genomic profiling reaches a minority of patients even in rich countries, and results rarely rejoin outcome data. Genomics England, AACR Project GENIE and national programmes in the Netherlands and Denmark show what pooled genomics plus outcomes can do. The proposal is universal whole-genome or comprehensive panel sequencing plus germline testing at diagnosis as a funded standard, with mandatory return of de-identified genomic, treatment and outcome data to a federated national learning system that publishes evidence for rare variants, drug response and hereditary risk.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos, Comprehensive genomic profiling.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Inherited risk is mostly unidentified, Whole-exome & whole-genome sequencing, Germline (hereditary) testing.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos, Comprehensive genomic profiling.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Germline vs somatic mutations, Inherited risk is mostly unidentified, Germline (hereditary) testing.